Involvement of interaction between Fractalkine and CX3CR1 in cytotoxicity of natural killer cells against tumor cells

Oncology Reports

Volumn 15, Issue 2, 2006, Pages 485-488

  Zhang, Xiaojun ^a   Wei, Haiming ^a   Wang, Hui ^a   Tian, Zhigang ^a  

^a UNIVERSITY OF SCIENCE AND TECHNOLOGY OF CHINA   (China)

Author keywords

Chemokine; CX3CR1; Fractalkine; Nature killer cells; Tumor

Indexed keywords

CHEMOKINE (C X3 C MOTIF) LIGAND 1; CHEMOKINE (C-X3-C MOTIF) LIGAND 1; CHEMOKINE RECEPTOR; CX3C CHEMOKINE; CX3CR1 PROTEIN, HUMAN; MEMBRANE PROTEIN;

ARTICLE; CYTOTOXICITY; FLOW CYTOMETRY; HUMAN; IMMUNOLOGY; METABOLISM; NATURAL KILLER CELL; NEOPLASM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL LINE;

CELL LINE, TUMOR; CHEMOKINES, CX3C; CYTOTOXICITY, IMMUNOLOGIC; FLOW CYTOMETRY; HUMANS; KILLER CELLS, NATURAL; MEMBRANE PROTEINS; NEOPLASMS; RECEPTORS, CHEMOKINE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 33744466850     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.15.2.485     Document Type: Article

References (30)

1. Gerard C and Rollins BJ: Chemokines and disease. Nat Immunol 2: 108-115, 2001. (Pubitemid 33707927)
2. Rossi D and Zlotnik A: The biology of chemokines and their receptors. Annu Rev Immunol 18: 217-242, 2000.
3. Bazan JF, Bacon KB, Hardiman G, et al: A new class of membrane-bound chemokine with a CX3C motif. Nature 385: 640-644, 1997.
4. Pan Y, Lloyd C, Zhou H, et al: Neurotactin, a membraneanchored chemokine upregulated in brain inflammation. Nature 387: 611-617, 1997. (Pubitemid 27248766)
5. Imai T, Hieshima K, Haskell C, et al: Identification and molecular characterization of fractalkine receptor CX3CR1, which mediates both leukocyte migration and adhesion. Cell 91: 521-530, 1997. (Pubitemid 27508241)
6. Garton KJ, Gough PJ, Blobel CP, et al: Tumor necrosis factor-alpha- converting enzyme (ADAM17) mediates the cleavage and shedding of fractalkine (CX3CL1). J Biol Chem 276: 37993-38001, 2001.
7. Tsou CL, Haskell CA and Charo IF: Tumor necrosis factor-alpha-converting enzyme mediates the inducible cleavage of fractalkine. J Biol Chem 276: 44622-44626, 2001.
8. Chapman GA, Moores K, Harrison D, Campbell CA, Stewart BR and Strijbos PJ: Fractalkine cleavage from neuronal membranes represents an acute event in the inflammatory response to excytotoxic brain damage. J Neurosci 20: RC87, 2000.
9. Soriano SG, Amaravadi LS, Wang YF, et al: Mice deficient in fractalkine are less susceptible to cerebral ischemia-reperfusion injury. J Neuroimmunol 125: 59-65, 2002. (Pubitemid 34327454)
10. Ludwig A, Berkhout T, Moores K, Groot P and Chapman G: Fractalkine is expressed by smooth muscle cells in response to IFN-gamma and TNF-alpha and is modulated by metalloproteinase activity. J Immunol 168: 604-612, 2002. (Pubitemid 34049559)
11. Matsumiya T, Imaizumi T, Fujimoto K, et al: Soluble interleukin-6 receptor alpha inhibits the cytokine-induced fractalkine/CX3CL1 expression in human vascular endothelial cells in culture. Exp Cell Res 269: 35-41, 2001. (Pubitemid 32848487)
12. Yoneda O, Imai T, Nishimura M, et al: Membrane-bound form of fractalkine induces IFN-gamma production by NK cells. Eur J Immunol 33: 53-58, 2003. (Pubitemid 36157642)
13. Zujovic V, Benavides J, Vige X, Carter C and Taupin V: Fractalkine modulates TNF-alpha secretion and neurotoxicity induced by microglial activation. Glia 29: 305-315, 2000. (Pubitemid 30121421)
14. Umehara H and Imai T: Role of fractalkine in leukocyte adhesion and migration and in vascular injury. Drug News Perspect 14: 460-464, 2001. (Pubitemid 34130742)
15. Boehme SA, Lio FM, Iejewski-Lenoir D, Bacon KB and Conlon PJ: The chemokine fractalkine inhibits Fas-mediated cell death of brain microglia. J Immunol 165: 397-403, 2000. (Pubitemid 30429532)
16. Shimoya K, Zhang Q, Tenma K, et al: Fractalkine (FRK) levels in amniotic fluid and its production during pregnancy. Mol Hum Reprod 9: 97-101, 2003. (Pubitemid 36285150)
17. Trinchieri G: Biology of natural killer cells. Adv Immunol 47: 187-376, 1989.
18. Biron CA: Activation and function of natural killer cell responses during viral infections. Curr Opin Immunol 9: 24-34, 1997.
19. Unanue ER: Inter-relationship among macrophages, natural killer cells and neutrophils in early stages of Listeria resistance. Curr Opin Immunol 9: 35-43, 1997.
20. Scharton-Kersten TM and Sher A: Role of natural killer cells in innate resistance to protozoan infections. Curr Opin Immunol 9: 44-51, 1997. (Pubitemid 27095896)
21. Scott P and Trinchieri G: The role of natural killer cells in hostparasite interactions. Curr Opin Immunol 7: 34-40, 1995.
22. Efsen E, Grappone C, De Franco RM, et al: Up-regulated expression of fractalkine and its receptor CX3CR1 during liver injury in humans. J Hepatol 37: 39-47, 2002. (Pubitemid 34713053)
23. Fraticelli P, Sironi M, Bianchi G, et al: Fractalkine (CX3CL1) as an amplification circuit of polarized Th1 responses. J Clin Invest 107: 1173-1181, 2001. (Pubitemid 32422914)
24. Yoneda O, Imai T, Goda S, et al: Fractalkine-mediated endothelial cell injury by NK cells. J Immunol 164: 4055-4062, 2000. (Pubitemid 30215060)
25. Robinson LA, Nataraj C, Thomas DW, et al: The chemokine CX3CL1 regulates NK cell activity in vivo. Cell Immunol 225: 122-130, 2003. (Pubitemid 38091556)
26. Lavergne E, Combadiere B, Bonduelle O, et al: Fractalkine mediates natural killer-dependent antitumor responses in vivo.Cancer Res 63: 7468-7474, 2003. (Pubitemid 37413490)
27. Guo J, Chen T, Wang B, et al: Chemoattraction, adhesion and activation of natural killer cells are involved in the antitumor immune response induced by fractalkine/CX3CL1. Immunol Lett 89: 1-7, 2003. (Pubitemid 37289511)
28. Guo J, Zhang M, Wang B, et al: Fractalkine transgene induces T-cell-dependent antitumor immunity through chemoattraction and activation of dendritic cells. Int J Cancer 103: 212-220, 2003. (Pubitemid 35461513)
29. Xin H, Kikuchi T, Andarini S, et al: Antitumor immune response by CX3CL1 fractalkine gene transfer depends on both NK and T cells. Eur J Immunol 35: 1371-1380, 2005. (Pubitemid 40691418)
30. Ohta M, Tanaka F, Yamaguchi H, Sadanaga N, Inoue H and Mori M: The high expression of Fractalkine results in a better prognosis for colorectal cancer patients. Int J Oncol 26: 41-47, 2005.